Sanofi

News

Doctor in the hand shows the scanning of the lung of the person.

NICE changes stance on Sanofi's Dupixent for severe asthma

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug.

News

Actemra shortage spills over to include Sanofi's rival Kevza...

Roche's Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to shortages.

News

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

News

Sanofi abandons mRNA COVID jab, despite positive trial

Sanofi has said that it won't develop its mRNA-based vaccine for COVID-19 any further, even though it seemed to work in an early-stage trial, and will focus instead on another candidate par

News

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).

News

Sanofi snaps up Kadmon and its transplant drug Rezurock

Less than a month after Kadmon Pharma launched its first product – Rezurock for a complication of organ transplants – the New York company has agreed to be bought by Sanofi in a $1.9 billio

NICE changes stance on Sanofi's Dupixent for severe asthma

Actemra shortage spills over to include Sanofi's rival Kevza...

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Sanofi abandons mRNA COVID jab, despite positive trial

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

Sanofi snaps up Kadmon and its transplant drug Rezurock

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Sanofi

Editor's Picks